CN
108-97-4
Applied Filters:
Keyword:'108-97-4'
Showing 1-30 of 291 results for "108-97-4" within Technical Documents
The Effective Use of Protein Kinase Inhibitors
114 113 90 107 102 97 98 107
JNK1α1/SAPK1c 97 98 96 49 104 96 102 111 101 93 97 108 101 98 92 89 95 91 100
JNK/SAPK1c
SAPK2a/p38 99 94 93 111 95 75 100
MILLIPLEX®MAP Human Myokine Panel is an optimized quantitative immunoassay that simultaneously measures 15 novel muscle-secreted factors
25 26 108 55 36 116 25 63 33 40 41 8977 40
std
7
37 37 34 32 120 58 39 130 30 97 45 64 41 13589 52
34 37 33 29 126 63 41
The Effective Use of Protein Kinase Inhibitors
114 113 90 107 102 97 98 107
JNK1α1/SAPK1c 97 98 96 49 104 96 102 111 101 93 97 108 101 98 92 89 95 91 100
JNK/SAPK1c
SAPK2a/p38 99 94 93 111 95 75 100
Quality Control Ranges - Milliplex Mouse Cytokine/Chemokine Magnetic Panel
IL-2 Control 1 108 - 223 pg/mL IL-15 Control 1 97 - 202 pg/mL
Control 2 597 - 1240 pg/mL Control 2 515 - 1071 pg/mL
Quality Control Range Sheet- MCY-112 and MCY-212
10 Control 1 97 – 202 pg/mL MIP-1 Control 1 102 – 212 pg/mL
Control 2 552 – 1146 pg/mL Control 2 520 – 1080 pg/mL Control 2 524 – 1089
Quality Control Range Sheet- MCY-112 and MCY2-212
10 Control 1 97 – 202 pg/mL MIP-1 Control 1 102 – 212 pg/mL
Control 2 552 – 1146 pg/mL Control 2 520 – 1080 pg/mL Control 2 524 – 1089
Improved Method for Adenovirus and Lentivirus Purification using the Fast-Trap™ Virus Purification and Concentration Kit
fraction.
MW 1 2 3
kDa
200
116
97
66
55
37
31
22
14
6
Hexon,
108 kDa
Removal
of BSA
MW 1 2
Quality Control Ranges: MILLIPLEX® MAP Human Cytokine/ Chemokine Magnetic Bead Panel
106 – 221 pg/mL IL-3 Control 1 97 – 202 pg/mL
Control 2 537 – 1115 pg/mL Control 2 485 – 1008 pg/mL
LABORATORY NOTEBOOK ISSUANCE PAGE
130 –117 45 — — 215 1.406
4–Methyl–2–pentanone
(or methyl isobutyl ketone) 0.801 117–118 –80 13 0.58 — 334 1.396
2–Methyl–1–propanol
(or isobutyl alcohol) 0.803 108 –108 27 4.70(15) 15.8(25) 200 1.396
Poster: Improved Method For Adeno and Lenti- Virus Purification and Titration
in
es
en
ce
104 105 106 107 108 109 1010
1 2 3 4
Hexon
Poster: Improved Method for Adeno and Lenti-Virus Purification and Titration
see Figure 4).
Number of IVP/ml determined by TCID50
-5 -4 -3 -2 -1 0 1 2
0.0
250000.0
500000.0
750000.0
1000000.0
1250000.0
lu
m
in
e
s
e
n
c
e
104 105 106 107 108 109
LABORATORY NOTEBOOK ISSUANCE PAGE
130 –117 45 — — 215 1.406
4–Methyl–2–pentanone
(or methyl isobutyl ketone) 0.801 117–118 –80 13 0.58 — 334 1.396
2–Methyl–1–propanol
(or isobutyl alcohol) 0.803 108 –108 27 4.70(15) 15.8(25) 200 1.396
LABORATORY NOTEBOOK ISSUANCE PAGE
130 –117 45 — — 215 1.406
4–Methyl–2–pentanone
(or methyl isobutyl ketone) 0.801 117–118 –80 13 0.58 — 334 1.396
2–Methyl–1–propanol
(or isobutyl alcohol) 0.803 108 –108 27 4.70(15) 15.8(25) 200 1.396
Data Sheet - E8652
of MDK1, a novel
receptor tyrosine kinase expressed in the murine
nervous system. Oncogene, 9, 97–108 (1995).
2. Flanagan, J.G. and P. Vanderhaegen, The ephrins
and Eph receptors in neural development
QUALITY CONTROL RANGES MILLIPLEX® MAP Ovine Cytokine/Chemokine Panel 1
Analyte QC Level Expected Range Units
IFNγ Control 1 18 - 37 pg/mL IL-17A Control 1 97 - 201 pg/mL
Control 2 52 - 108 pg/mL Control 2 263 - 547 pg/mL
Product Information Sheet - T9881
Society (London, UK: 1996), pp. 106, 108, 112.
3. Thong, K. W., et al., L-methionine catabolism in
trichomonads. Mol. Biochem. Parasitol., 23(3),
223-231 (1987).
4. Takeuchi, T., et al., Entamoeba
Quality Control Ranges: MILLIPLEX® MAP Human Cytokine/ Chemokine Magnetic Bead Panel
mL
IL-4 Control 1 87 - 181 pg/mL MIP-1 Control 1 124 - 257 pg/mL
Control 2 432 - 898 pg/mL
Product Information Sheet - R3501
R3501 Page 1 of 4
03/28/97 - ARO
RIFAMPICIN
Sigma Prod. No. R3501
CAS NUMBER: 13292-46-1
SYNONYMS: Tubocin; Sinerdol; Rimactan;
L-5103; Dione-21 Acetate; Archidyn; Arficin; 3-(4-
Methylpiperazinyliminomethyl
A New Vacuum-Based Method for Adenovirus Purification and Concentration
Sterilization
Table 1.
97-
3-
kDa
200-
116-
66-
55-
37-
22-
14-
6-
2-
31-
66-
kDa
200-
116-
55-
37-
Verfication summary-03-0202-00
3 MRD (1:4) 21.35 1.2 6% 85.38 4.7 6% -
3 1:8 11.00 0.6 6% 88.04 4.9 6% 103%
3 1:16 5.86 1.8 30% 93.80 28.4 30% 110%
3 1:32 2.88 0.3 11% 92.15 10.0 11% 108%
HMN713785
Verfication summary-03-0202-00
3 MRD (1:4) 21.35 1.2 6% 85.38 4.7 6% -
3 1:8 11.00 0.6 6% 88.04 4.9 6% 103%
3 1:16 5.86 1.8 30% 93.80 28.4 30% 110%
3 1:32 2.88 0.3 11% 92.15 10.0 11% 108%
HMN713785
Data Sheet - C8119
, 2545-2555 (2005).
3. Nerlov, C., Trends Cell Biol., 17, 318-324 (2007).
4. Fuchs, O., et al., Folia Biol. (Praha), 53, 97-108
(2007).
5. Schuster, M.B., and Porse, B.T., Biochem.
Biophys. Acta
Panorama Ab Microarray - Gene Regulation I List of Antibodies
Iβ M3567
107 PCNA
Data Sheet - P3618
(1988).
2. Heldin, C.-H., and Westermark, B., Trends Gene.,
5, 108 (1989).
3. Fellstrom, B., et al., Kidney Int., 36, 1099 (1989).
4. Terracio, L., et al., J. Cell Biol., 107, 1947 (1988).
5. Funa, K
Data Sheet - R4402
Regulator of Cullins) is developed in rabbit
using a synthetic peptide corresponding to amino acid
97-108 in the N-terminal region of human ROC1 as the
immunogen. The antiserum is purified using Protein
Analysis of Polynuclear Aromatic Hydrocarbons in Paprika Powder
22 Benzo[g,h,i]perylene 80% 5% 2.6 (5)
23 Dibenzo[a,l]pyrene 108% 12%
24 Dibenzo[a,e]pyrene 82% 5%
26 Dibenzo[a,i]pyrene 108% 15%
27 Dibenzo[a,h]pyrene 147% 36%
Analysis of Polynuclear
Anti-Calpain-2 Large Subunit (C3989)
m-calpain suggests an electrostatic
switch mechanism for activation by calcium. PNAS,
97, 588-592 (2000).
4. Ariyoshim, H., et al., Possible involvement of
m-calpain in vascular smooth muscle cell
Data Sheet - S5196
Gali, V. et al., Nature, 403, 108-112 (2000).
7. Moazed, D. et al., Curr. Opin. Cell Biol., 13, 232-
238 (2001).
8. Smith, J.S. et al., Proc. Natl. Acad. Sci. USA, 97,
6658-6663 (2000).
Data Sheet - SAB4200517
702-713 (2005).
7. Lu, Z.H., et al., Cancer Res., 70, 3287-3298.
8. Zou, J., et al., Dev. Cell, 20, 97-108 (2011).
ER,RC,PHC 10/12-1
Data Sheet - SAB4200410
713 (2005).
7. Lu, Z.H., et al., Cancer Res., 70, 3287-3298.
8. Zou, J., et al., Dev. Cell, 20, 97-108 (2011).
ER,RC,PHC-04/12-1
Page 1 of 10